[10 years of testing of the HER2 status in breast cancer in Russia].
The paper analyzes 10 years' experience in HER2 status testing in breast cancer in Russia. The ASCO/CAP HER2 testing guidelines adaptable to the work of pathologists in Russia are considered.
G A
GA
Frank
Iu Iu
IuIu
Andreeva
I Iu
IIu
Vinogradov
S B
SB
Glatko
M Z
MZ
Gorelik
L E
LE
Zavalishina
E E
EE
Leenman
A E
AE
Matsionis
S V
SV
Petrov
S V
SV
Sazonov
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000295:instrumentation / Q000379:methods; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D012015:Reference Standards; D012426:Russia / Q000453:epidemiology; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human